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Background. HIV is associated with dysfunctional cellular and humoral immunity. The effects of co-infection with hepatitis C virus (HCV) on immune reconstitution are controversial. The utility of monitoring B-cell lymphocyte counts in HIV patients has not been well studied. In the present study, we compare the effect of antiretroviral therapy (ART) on CD4 and B-cell counts in HIV mono-infected (HIV + /HCV-) and HCV co-infected (HIV + /HCV+) patients.
Methods. Retrospective observational cohort of 160 HIV-infected patients (39 with HCV co-infection) who suppressed plasma viral load (VL) to undetectable levels within one-year of ART initiation. We reviewed baseline clinical and demographic variables, and CD4 and B-cell counts at two time points: prior to ART initiation and after 9-15 months of persistently undetectable VL ( post-ART). A multiple general linear regression model was used to test for significant associations between predictor variables and change in B-cell counts after adjusting for pre-ART levels as well as covariates significant in the univariate analysis.
Results. The median absolute pre-to post-ART increase in CD4 and B-cell counts did not differ significantly between the 2 groups (table). In HIV + /HCV-and HIV + / HCV+ patients, the % increase in B-cell and CD4 count were strongly correlated (Spearman's R 0.58 and R 0.65, respectively, P < 0.001). In a multiple regression model adjusting for pre-ART B-cell count, HCV-co-infected patients experienced a not statistically significant 15% greater rise in B-cell counts, compared to mono-infected group (P = 0.08). Median increase (IQR); cells/mL plasma; **% increase from pre-ART count.
CD4 and B-cell increases
Conclusion. In this cohort of patients with 9-15 months of suppressed viremia after ART initiation, HCV co-infection did not significantly influence the magnitude of reconstitution of CD4 or B cell counts. Changes in B-cell and CD4 count were strongly correlated. Our data provide support to recent guidelines against routine monitoring of B cell counts.
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